Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder

Stock Information for Awakn Life Sciences

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Awakn Life Sciences

Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Awakn Life Sciences Announces Credit Facility
Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites
Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program
Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.